Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer – August 2022
The urgent need for effective preventive vaccine and efficacious therapeutics for COVID-19 has given rise to an unprecedented pace of R&D by the biopharmaceutical industry, coupled with substantial investment by governments, non-profit agencies, and other stakeholders. There are currently more than 1,800 assets in development for COVID-19, the majority of which are very early-stage or have little data available.
The Coronavirus Disease 2019 (COVID-19) clinical and commercial analyzer report looks at the data from clinical trials for vaccines and therapeutics either currently marketed or in the pipeline. The data is assessed, and the different products are compared against each other both clinically and commercially.
Key Therapeutics in the COVID-19 Clinical and Commercial Market
Some of the key therapeutics in the COVID-19 clinical and commercial market are remdesivir, dexamethasone, favipiravir, sotrovimab, tocilizumab, nirmatrelvir + ritonavir, bebtelovimab (LYCoV-1404MAB), tixagevimab + cilgavimab, molnupiravir, and baricitinib.
Key Vaccines in the COVID-19 Clinical and Commercial Market
Some of the key vaccines in the COVID-19 clinical and commercial market are BNT162b2, BBIBP-CorV, mRNA-1273, Gam-COVID-Vac, Aurora-CoV, AZD1222, NVX-CoV2373, BBV152, Ad5-nCoV, and COVID-19 Vaccine (Vero Cell).
Key Companies in the COVID-19 Clinical and Commercial Market
Some of the key companies in the COVID-19 clinical and commercial market are Pfizer, BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Novavax, CureVac, Sanofi, GlaxoSmithKline, and Arcturus.
For more information on the COVID-19 clinical and commercial market, download a free report sample
COVID-19 Clinical and Commercial Market Report Overview
| Key Therapeutics | remdesivir, dexamethasone, favipiravir, sotrovimab, tocilizumab, nirmatrelvir + ritonavir, bebtelovimab (LYCoV-1404MAB), tixagevimab + cilgavimab, molnupiravir, and baricitinib |
| Key Vaccines | BNT162b2, BBIBP-CorV, mRNA-1273, Gam-COVID-Vac, Aurora-CoV, AZD1222, NVX-CoV2373, BBV152, Ad5-nCoV, and COVID-19 Vaccine (Vero Cell) |
| Key Companies | Pfizer, BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Novavax, CureVac, Sanofi, GlaxoSmithKline, and Arcturus |
Scope
This report provides:
- In-depth assessment of the marketed and pipeline products for COVID-19, analyzing the clinical and commercial aspects of the products against one another.
- A weighted view of the impact of the Omicron variant on the products.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of marketed and pipeline products and technologies, and by identifying the companies with the most robust pipeline and marketed products.
- Understand the strengths and weaknesses of pipeline and marketed products, and how they compare against one another.
- Develop business strategies by understanding the trends shaping and driving the COVID-19 market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global COVID-19 vaccine and therapeutic market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Players
Table of Contents
Frequently Asked Questions
Some of the key therapeutics in the COVID-19 clinical and commercial market are remdesivir, dexamethasone, favipiravir, sotrovimab, tocilizumab, nirmatrelvir + ritonavir, bebtelovimab (LYCoV-1404MAB), tixagevimab + cilgavimab, molnupiravir, and baricitinib.
Some of the key vaccines in the COVID-19 clinical and commercial market are BNT162b2, BBIBP-CorV, mRNA-1273, Gam-COVID-Vac, Aurora-CoV, AZD1222, NVX-CoV2373, BBV152, Ad5-nCoV, and COVID-19 Vaccine (Vero Cell).
Some of the key companies in the COVID-19 clinical and commercial market are Pfizer, BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Novavax, CureVac, Sanofi, GlaxoSmithKline, and Arcturus.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Pharmaceuticals reports